Epizyme, Inc. has terminated its study of tazemetostat with enzalutamide or abiraterone/​prednisone in participants with advanced prostate cancer (CELLO-1) due to a sponsor decision unrelated to safety concerns.
1 Discontinued Research Program
All entries for: Epizyme
December 9, 2024
Epizyme
Discontinued Research
Boston, MA
51-200 employees
Disease Area: Multiple, Oncology, Rare Diseases
Drug Type: Small Molecule
